Metavant Sciences
  • Contact

NEWS

Jul 09
0

Metavant and Poxel Announce Positive Topline Safety and PK/PD Results of Imeglimin in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 3b/4

By Alta Berri | Imeglimin

Trial met its primary objective with imeglimin observed to have a favorable safety and tolerability profile in patients with type 2 diabetes and chronic kidney disease stages 3b/4 Pharmacokinetics (PK)…

Read More
  • Contact


  • Privacy Policy
  • Terms of Use

© 2021 Metavant Sciences.

  • Contact